Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Micromet Inc (MITI) -- Ignore unavailable to you. Want to Upgrade?

To: ejgopher who wrote (63)	3/13/2009 1:31:53 PM
From: Biomaven	Read Replies (1) \| Respond to of 196

Practically speaking you have to compare those SAE's and outcomes with the alternatives, which mostly constitute retreatment with Rituxan plus high-dose chemo and autologous stem cell transplant. You're going to see comparable mortality and morbidity in the alternative treatment regimes as well. From the call it did sound like they were more excited by the results in post-chemo ALL though - my guess is that this is where they want to focus for now and it may well be too niche of an indication to fit well with AZN. At the end of the day AZN has retained an option on the program, and is essentially paying for the option by paying for the manufacturing facility. Peter